<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00456235</url>
  </required_header>
  <id_info>
    <org_study_id>I06024</org_study_id>
    <nct_id>NCT00456235</nct_id>
  </id_info>
  <brief_title>Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors</brief_title>
  <acronym>MONOCEPT</acronym>
  <official_title>Interruption of the Calcineurine Inhibitors (ICN) and Introduction of Mycophenolate Mofetil (MMF) in Liver Transplant Patients With Side Effects Due to ICN: Study of the Reduction of the Risks of Rejection by Mycophenolate Mofetil Therapeutic Drug Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <brief_summary>
    <textblock>
      The aim of this project is to determine whether, in liver transplant patients with side&#xD;
      effects due to ICN, the use of MMF in monotherapy can be optimised by dose adjustment based&#xD;
      on the area under the curve (AUC) of mycophenolic acid (MPA). It involves a multicentre phase&#xD;
      IV trial with direct individual benefit.&#xD;
&#xD;
      A population of 130 liver transplant patients at 2 to 10 years post-transplant, showing&#xD;
      significant clinical ICN side effects and being given bitherapy by ICN +MMF will be included&#xD;
      and randomised 1:1 in two arms:&#xD;
&#xD;
        -  Arm 1: progressive interruption of ICN after obtaining an AUC of MPA of 50 mg.h/l,&#xD;
           followed by MMF monotherapy with dose adjustment based on the AUC of MPA,&#xD;
&#xD;
        -  Arm 2: continuation of the ICN+MMF bitherapy without MMF therapeutic drug monitoring.&#xD;
&#xD;
      The main judgement criterion will be the incidence of acute rejection in the 2 groups at 6&#xD;
      months. The secondary judgment criterion will be the evaluation of the benefit of stopping&#xD;
      ICN on the side effects caused by these drugs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of biopsy proven acute rejection treated</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of biopsy proven acute rejection treated with corticoids or requiring a re-introduction of ICN in arm 1 -- or an increase of ICN in arm 2 -- 6 months after the interruption of ICN (arm 1) or after randomization (arm 2).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>adjument MMF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adjusting the dose according to the MMF AUC of mycophenolic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>continued treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continued treatment empirically usual</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophénolate Mofétil</intervention_name>
    <arm_group_label>adjument MMF</arm_group_label>
    <arm_group_label>continued treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporine A</intervention_name>
    <arm_group_label>adjument MMF</arm_group_label>
    <arm_group_label>continued treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <arm_group_label>adjument MMF</arm_group_label>
    <arm_group_label>continued treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with first liver transplantion or retransplantation since more than 6 months:&#xD;
             with a post-transplant lapse of time of 2 to 10 years and showing one of the following&#xD;
             adverse effects of ICN:&#xD;
&#xD;
          -  Renal insufficiency defined by a creatinine clearance &lt;50ml/mn (calculated or&#xD;
             estimated according to the Cockcroft formula)&#xD;
&#xD;
          -  Arterial hypertension not controlled by an anti-hypertensive bitherapy&#xD;
&#xD;
          -  Diabetes mellitus (fasting glycaemia &gt;7.0mmol/l), whether treated or not&#xD;
&#xD;
          -  Neuromuscular toxicity&#xD;
&#xD;
          -  Immunosuppression by cyclosporine or tacrolimus and MMF&#xD;
&#xD;
          -  Hepatic biopsy performed within the 6 months preceding the inclusion for the patients&#xD;
             with a post-transplant period of &lt;5 years and in the 12 months preceding the inclusion&#xD;
             for patients with a post transplant period of &gt;5 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute rejection within the 6 months preceding the screening&#xD;
&#xD;
          -  Previous history of cortico-resistant rejection&#xD;
&#xD;
          -  Chronic rejection&#xD;
&#xD;
          -  Significant ductopenia (absence of inter-lobule biliary canals in more than 30% of the&#xD;
             portal tracts) on the pre-screening biopsy.&#xD;
&#xD;
          -  Existence of a pre-transplantation diabetes mellitus.&#xD;
&#xD;
          -  Liver transplantation for auto-immune hepatitis or primary sclerosing cholangitis&#xD;
&#xD;
          -  Patients transplanted for viral C cirrhosis with reinfection lesions of the&#xD;
             transplanted organ, rendering treatment by ribarivine + interferon conceivable in the&#xD;
             year following inclusion.&#xD;
&#xD;
          -  Counter-indications to MMF (anaemia, leucopenia)&#xD;
&#xD;
          -  Immunosuppression by sirolimus, everolimus, azathioprine or corticoids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre MARQUET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Limoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>April 3, 2007</study_first_submitted>
  <study_first_submitted_qc>April 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2007</study_first_posted>
  <last_update_submitted>April 16, 2013</last_update_submitted>
  <last_update_submitted_qc>April 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

